Forsta AP Fonden lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.8% in the third quarter, HoldingsChannel.com reports. The fund owned 322,082 shares of the company’s stock after selling 112,173 shares during the period. Johnson & Johnson makes up about 1.5% of Forsta AP Fonden’s portfolio, making the stock its 13th largest holding. Forsta AP Fonden’s holdings in Johnson & Johnson were worth $41,874,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. BlackRock Inc. lifted its holdings in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after buying an additional 3,289,763 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after buying an additional 2,581,562 shares during the period. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after buying an additional 2,482,843 shares during the period. Institutional investors own 65.72% of the company’s stock.

Several brokerages have recently weighed in on JNJ. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Monday. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Citigroup upped their target price on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $146.01.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $141.83 on Wednesday. The company has a market capitalization of $397,981.06, a price-to-earnings ratio of 20.75, a PEG ratio of 2.77 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.58 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.37%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is 58.33%.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/24/forsta-ap-fonden-has-41-87-million-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.